Opinions
Dr. Richard Evans
Teva Pharmaceutical
TEVA-N
COMMENT
Jan 25, 2017
$33.680
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
DON'T BUY
They went from an in incredibly well managed drug company and then management decided to develop their own drugs and make mistakes. It is difficult to unwind these problems. Turning around a company like this will be difficult because of the debt. This is a highly speculative stock.
biotechnology
pharmaceutical
HOLD
Generic brand companies like Teva have struggled in the last 5 years has they competed with each others. Pfizer is in the process of buying one of their competitors and the Pfizer stock dropped 5$ on the announcement. Doesn't own Teva, purchased United Heatlth recently. You can hold but it's not a name he would hold due to the risk and they have no value added.
biotechnology
pharmaceutical
DON'T BUY
Advertising
One of the generic companies that focuses on the top of the market. They tend to have the newer generics. The bad news is that they are selling in the US to 3 joint ventures. The wholesalers and retailers got together to form joint ventures which controls 80% of generics, so they get much lower selling prices. The trick is to be very efficient in manufacturing, to be able to meet the bids as well as being early in launching drugs that have just gone off patent. A tougher game to play than it used to be. Operationally, the company historically has been very good. It has sold off, and is reasonably attractive.